<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Causes of hyperprolactinemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Causes of hyperprolactinemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Causes of hyperprolactinemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Snyder, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Cooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prolactin is secreted solely by the lactotroph cells of the pituitary gland. As a result, hyperprolactinemia results almost exclusively from diseases that cause hypersecretion of prolactin by lactotroph cells. Some of these causes are physiologic and others pathologic.
        </p>
        <p>
         This topic will review the major causes of hyperprolactinemia. The clinical manifestations, diagnosis, and treatment are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6638.html" rel="external">
          "Clinical manifestations and evaluation of hyperprolactinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">
          "Management of hyperprolactinemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PHYSIOLOGIC CAUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum prolactin concentrations normally increase substantially during pregnancy and to a lesser degree in response to nipple stimulation during breastfeeding, physical exertion, and stress. The upper normal value for serum prolactin in most laboratories is approximately 20 ng/mL (20 mcg/L SI units).
        </p>
        <p>
         Meals may stimulate prolactin secretion slightly. Thus, if the prolactin concentration is only slightly high (up to 40 ng/mL [40 mcg/L] in males and postmenopausal females and up to 50 ng/mL [50 mcg/L] in premenopausal females), it should be repeated on a fasting sample before the patient is considered to have hyperprolactinemia.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum prolactin increases throughout pregnancy, reaching a peak at delivery (
         <a class="graphic graphic_figure graphicRef82454" href="/z/d/graphic/82454.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. The magnitude of the increase, however, is quite variable; in one study, the mean value at term was 207 ng/mL, but the range was from 35 to 600 ng/mL (35 to 600 mcg/L SI units) [
         <a href="#rid1">
          1
         </a>
         ]. The probable cause of the hyperprolactinemia is the increasing serum estradiol concentrations during pregnancy. By six weeks after delivery, estradiol secretion has decreased, and the basal serum prolactin concentration is usually normal, even when the mother is breastfeeding.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Nipple stimulation and breast examinations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nipple stimulation during breastfeeding increases serum prolactin concentrations, presumably via a neural pathway. The magnitude of the increase is directly proportional to the degree of preexisting lactotroph hyperplasia due to estrogen. In the first weeks postpartum, as an example, the serum prolactin concentration increases up to 300 ng/mL above baseline in response to suckling (
         <a class="graphic graphic_figure graphicRef59612" href="/z/d/graphic/59612.html" rel="external">
          figure 2
         </a>
         ); in contrast, several months after delivery, the increase in prolactin in response to suckling in the breastfeeding woman is usually less than 10 ng/mL (10 mcg/L SI units) above baseline (
         <a class="graphic graphic_figure graphicRef59612" href="/z/d/graphic/59612.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         In nonlactating females and males, nipple stimulation, breast imaging (mammography, ultrasound) [
         <a href="#rid2">
          2
         </a>
         ], or breast examination does
         <strong>
          not
         </strong>
         increase prolactin secretion [
         <a href="#rid3">
          3,4
         </a>
         ]. Therefore, prolactin may be measured after a breast examination.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Stress
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stress of any kind, physical or psychological, can cause an increase in the serum prolactin concentration. As with all stimuli of prolactin secretion, women have greater increases than men, presumably due to the effect of their higher serum estradiol concentrations on the lactotroph cells. The magnitude of the increase in prolactin in response to stress is small, so the values rarely exceed 40 ng/mL (40 mcg/L SI units).
        </p>
        <p class="headingAnchor" id="H87853567">
         <span class="h1">
          PATHOLOGIC CAUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperprolactinemia due to hypothalamic-pituitary disorders includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lactotroph adenomas (prolactinomas), which are benign tumors of the lactotroph cell. Serum prolactin concentrations in patients who have lactotroph adenomas can range from minimally elevated to 50,000 ng/mL (50,000 mcg/L SI units); in comparison, in hyperprolactinemia due to other causes, the concentrations rarely exceed 200 ng/mL (200 mcg/L SI units) (
         <a class="graphic graphic_figure graphicRef72540" href="/z/d/graphic/72540.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Lactotroph adenomas'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conditions associated with decreased dopaminergic inhibition of prolactin secretion. (See
         <a class="local">
          'Decreased dopaminergic inhibition of prolactin secretion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disease in or near the hypothalamus or pituitary that interferes with the secretion of dopamine or its delivery to the pituitary gland. (See
         <a class="local">
          'Other hypothalamic or pituitary disorders'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Lactotroph adenomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lactotroph adenomas, like other pituitary adenomas, arise from monoclonal expansion of a single cell that has presumably undergone somatic mutation [
         <a href="#rid6">
          6,7
         </a>
         ]. The pituitary tumor transforming gene is overexpressed in most lactotroph adenomas [
         <a href="#rid8">
          8,9
         </a>
         ]. It also appears to play a role in tumor invasiveness since expression is increased in tumors that invade the sphenoid bone.
        </p>
        <p>
         Most adenomas that secrete prolactin and cause hyperprolactinemia are comprised solely of lactotroph cells; however, approximately 10 percent are comprised of both lactotroph and either somatotroph or somatomammotroph cells and, therefore, secrete growth hormone as well as prolactin [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Lactotroph adenomas are relatively common; they account for approximately 30 to 40 percent of all clinically recognized pituitary adenomas. The diagnosis is made more frequently in women than in men, especially between the ages of 20 and 40 years [
         <a href="#rid11">
          11
         </a>
         ], presumably because of the sensitivity of menses to disruption by hyperprolactinemia. However, the adenomas that occur in men are usually larger, in part due to the lack of symptoms or delay in seeking medical attention for symptoms such as erectile dysfunction [
         <a href="#rid12">
          12
         </a>
         ]. In addition, the adenomas in men may have an inherently greater rate of growth [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Most lactotroph adenomas are sporadic, but they can rarely occur as part of the multiple endocrine neoplasia type 1 (MEN1) syndrome [
         <a href="#rid13">
          13
         </a>
         ]. Almost all lactotroph tumors are benign, but a rare tumor can be malignant and metastasize [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">
          "Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Prolactin secretion by lactotroph adenomas is generally characterized by both efficiency and proportionality:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As a result of their efficiency, even microadenomas (&lt;1 cm in diameter) typically secrete sufficient prolactin to cause hyperprolactinemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As a result of their proportionality, serum prolactin concentrations tend to vary with adenoma size. Adenomas &lt;1 cm in diameter are typically associated with serum prolactin values below 200 ng/mL (200 mcg/L SI units), those approximately 1.0 to 2.0 cm in diameter with values between 200 and 1000 ng/mL (1000 mcg/L SI units), and those greater than 2.0 cm in diameter with values above 1000 ng/mL (1000 mcg/L SI units) (
         <a class="graphic graphic_figure graphicRef72540" href="/z/d/graphic/72540.html" rel="external">
          figure 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Some lactotroph macroadenomas are associated with only modest elevations of prolactin because of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adenomas that are not well differentiated. These also respond less well to dopamine agonists than the more typical adenomas. (See
         <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">
          "Management of hyperprolactinemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adenomas that are largely cystic, so only a small portion of the mass is cellular and producing prolactin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An artifact in the immunoradiometric assay for prolactin called the "hook effect." This can be obviated by dilution of the sera, which will allow a true assessment of the prolactin concentration [
         <a href="#rid15">
          15-17
         </a>
         ]. This artifact is uncommon.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Decreased dopaminergic inhibition of prolactin secretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several conditions interfere with normal dopamine inhibition of prolactin secretion. These include damage to the dopaminergic neurons of the hypothalamus, pituitary stalk section, or drugs that block dopamine receptors on lactotroph cells (
         <a class="graphic graphic_table graphicRef75914" href="/z/d/graphic/75914.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Other hypothalamic or pituitary disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any disease in or near the hypothalamus or pituitary that interferes with the secretion of dopamine or its delivery to the pituitary can cause hyperprolactinemia [
         <a href="#rid5">
          5
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">
          "Causes, presentation, and evaluation of sellar masses"
         </a>
         ). These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors of the hypothalamus, both benign (eg, craniopharyngiomas) and malignant (eg, metastatic breast carcinoma). These and infiltrative diseases, below, are not as common causes of elevated prolactin as pituitary adenomas, lactotroph, and others.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infiltrative diseases of the hypothalamus (eg, sarcoidosis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Section of the hypothalamic-pituitary stalk (eg, due to head trauma or surgery).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adenomas of the pituitary other than lactotroph adenomas.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H87853791">
         <span class="h1">
          DRUG INDUCED
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of drugs may cause hyperprolactinemia (
         <a class="graphic graphic_table graphicRef75914" href="/z/d/graphic/75914.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid18">
          18,19
         </a>
         ]. Although drugs can cause hyperprolactinemia, they do not cause lactotroph adenomas. In medication-induced hyperprolactinemia, serum prolactin concentrations are typically in the 25 to 100 ng/mL (25 to 100 mcg/L) range. One exception is the antipsychotic drug,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , which may be associated with serum prolactin concentrations as high as 200 ng/mL (200 mcg/L) [
         <a href="#rid19">
          19-21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H37630182">
         <span class="h2">
          Antipsychotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antipsychotics are the most common cause of pharmacologically induced hyperprolactinemia. Some of the antipsychotic drugs are known dopamine D
         <sub>
          2
         </sub>
         receptor antagonists and raise serum prolactin by that mechanism. These include
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , phenothiazines, and
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         (
         <a class="graphic graphic_table graphicRef75914" href="/z/d/graphic/75914.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid22">
          22,23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">
          "First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
         Serum prolactin concentrations increase within hours after acute administration of these drugs and return to normal within two to four days after cessation of chronic therapy [
         <a href="#rid23">
          23
         </a>
         ]. The magnitude of the elevation varies with the drug. As an example,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         raises the serum prolactin concentration by an average of 17 ng/mL (17 mcg/L SI units), whereas
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         may raise it by 45 to 80 ng/mL (45 to 80 mcg/L SI units) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Among newer antipsychotics, the highest prevalence of hyperprolactinemia has been observed with amisulpride (89 percent), an atypical antipsychotic available in some countries but not the United States; it has not been observed with
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         (
         <a class="graphic graphic_table graphicRef75914" href="/z/d/graphic/75914.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid24">
          24
         </a>
         ]. The anticonvulsant
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         has also been used as an antipsychotic, and since it has an inhibitory effect on prolactin secretion, the suggestion has been made that it could be used in psychiatric conditions when hyperprolactinemia should be avoided [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H37629775">
         <span class="h2">
          SSRIs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selective serotonin reuptake inhibitors (SSRIs) cause little, if any, increase in the serum prolactin concentration (
         <a class="graphic graphic_table graphicRef75914" href="/z/d/graphic/75914.html" rel="external">
          table 1
         </a>
         ). In one study [
         <a href="#rid26">
          26
         </a>
         ], 20 mg of
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         a day caused no increase in the serum prolactin concentration after one week but did cause a slight increase, although still to only high-normal to slightly high values, after three weeks.
        </p>
        <p>
         In another study in patients receiving
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         chronically [
         <a href="#rid27">
          27
         </a>
         ], the mean basal serum prolactin concentration was no different from that in untreated patients with similar diseases. Thus, SSRIs do not appear to cause clinically significant hyperprolactinemia.
        </p>
        <p class="headingAnchor" id="H37629840">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other drugs have been associated with hyperprolactinemia, including (
         <a class="graphic graphic_table graphicRef75914" href="/z/d/graphic/75914.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          Metoclopramide
         </a>
         [
         <a href="#rid28">
          28
         </a>
         ] and
         <a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">
          domperidone
         </a>
         [
         <a href="#rid29">
          29
         </a>
         ] are gastric motility drugs. Like some of the antipsychotics, dopamine D
         <sub>
          2
         </sub>
         receptor antagonists raise serum prolactin by that mechanism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The antihypertensive drug
         <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">
          methyldopa
         </a>
         , which is not commonly used now, increases prolactin secretion by a similar mechanism to the gastric motility drugs. Methyldopa inhibits dopamine synthesis [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         may raise serum prolactin concentrations [
         <a href="#rid31">
          31
         </a>
         ], but other calcium channel blockers do not [
         <a href="#rid32">
          32
         </a>
         ]. The mechanism of this verapamil-induced increase is not known.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one report, hyperprolactinemia occurred in 8.5 percent of 449 men taking
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         , as compared with only 3 percent of control men [
         <a href="#rid33">
          33
         </a>
         ]. The elevated serum prolactin concentration persisted during continued drug administration in 14 of 15 men and returned to normal in all nine after the drug was stopped.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          OTHER CAUSES
         </span>
        </p>
        <p class="headingAnchor" id="H61085649">
         <span class="h2">
          Germline loss-of-function mutation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A germline, loss-of-function mutation in the prolactin receptor gene (
         <em>
          PRLR
         </em>
         ) resulting in prolactin insensitivity has been identified as a cause of familial hyperprolactinemia [
         <a href="#rid34">
          34
         </a>
         ]. The family included three sisters: two with oligomenorrhea, one with primary infertility, and all with serum prolactin concentrations in the 100 to 180 ng/mL range (4.35 to 7.83 nmol/L) and normal pituitary magnetic resonance imaging (MRI). The sisters' father and one of the sisters' sons also carried the mutation; in contrast with the affected female family members, their serum prolactin concentrations were only minimally elevated (20 to 21 ng/mL [0.87 to 0.91 nmol/L]), and they had no other clinical manifestations.
        </p>
        <p>
         The heterozygous mutation in
         <em>
          PRLR
         </em>
         results in an amino acid change from histidine to arginine at codon 188, resulting in a loss of downstream signaling by Janus kinase 2 (JAK2) and signal transducer and activator of transcription factor 5 (STAT5). The oligomenorrhea and infertility suggest that the hyperprolactinemia is having a biologic effect, which in turn suggests that there are functioning prolactin receptors in some tissues.
        </p>
        <p class="headingAnchor" id="H87853725">
         <span class="h2">
          Idiopathic hyperprolactinemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a substantial number of patients whose serum prolactin concentration is between 20 and 100 ng/mL (20 and 100 mcg/L SI units), no cause can be found. Although many of these patients may have microadenomas not visible on imaging studies, in most of them, the serum prolactin concentrations change little during follow-up for several years [
         <a href="#rid35">
          35-37
         </a>
         ]. In one report, as an example, only 1 of 59 patients who were followed for an average of 6.5 years developed a detectable pituitary adenoma, and approximately 20 percent had a normal serum prolactin concentration when it was last measured [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Estrogen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Estrogen increases prolactin secretion proportionate to the degree of estrogenization. The mechanism by which estrogen stimulates prolactin secretion appears to involve binding of estrogen to the estrogen receptor, which then binds to an estrogen response element on the prolactin gene in the lactotroph cell of the pituitary [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p>
         Amounts of estrogen that are physiologic for a woman increase the basal serum prolactin concentration minimally but explain the greater prolactin response of women compared with men to almost all physiologic stimuli [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Greater amounts of estrogen, such as occur in pregnancy, increase basal serum prolactin concentrations, as described above. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
        <p>
         The amount of estrogen in hormonal contraceptives generally does not cause hyperprolactinemia. (See
         <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">
          "Management of hyperprolactinemia", section on 'Treatment of women with estradiol'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Hypothyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypothyroidism predisposes to hyperprolactinemia. However, basal serum prolactin concentrations are normal in most hypothyroid patients [
         <a href="#rid41">
          41
         </a>
         ], and only the serum prolactin response to stimuli, such as thyrotropin-releasing hormone (TRH), is increased [
         <a href="#rid42">
          42
         </a>
         ]. In the few hypothyroid patients who have elevated basal serum prolactin concentrations, the values return to normal when the hypothyroidism is corrected [
         <a href="#rid43">
          43,44
         </a>
         ]. It is important to recognize hypothyroidism as a potential cause of an enlarged pituitary gland (due to thyrotroph hyperplasia, lactotroph hyperplasia, or both) and hyperprolactinemia and not to confuse this entity with a lactotroph adenoma. (See
         <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">
          "Causes, presentation, and evaluation of sellar masses"
         </a>
         .)
        </p>
        <p>
         The mechanism of hyperprolactinemia in hypothyroidism is not known. Both enhanced hypothalamic synthesis of TRH and increased pituitary responsiveness to TRH have been described [
         <a href="#rid42">
          42
         </a>
         ]. The management of hyperprolactinemia due to hypothyroidism is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">
          "Management of hyperprolactinemia", section on 'Hypothyroidism'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H87853588">
         <span class="h2">
          Decreased clearance of prolactin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two causes of hyperprolactinemia due to decreased clearance of prolactin include chronic renal failure and macroprolactinemia.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Macroprolactinemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Macroprolactinemia is an umbrella term used to describe aggregates of prolactin and antibodies (in particular, antiprolactin autoantibodies) that range in size from approximately 150 to 170 kD. The most common form of native prolactin in serum is 23 kD in size [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         These complexes are immunologically detectable but not biologically active, so they appear to cause no clinical abnormality. As an example, in a series of 55 women ages 18 to 55 years, none had a history of amenorrhea, eight had oligomenorrhea before age 40 years, and one had galactorrhea [
         <a href="#rid46">
          46
         </a>
         ]. All subjects had pituitary imaging; no macroadenomas and four microadenomas were seen (consistent with the prevalence of incidentalomas in the normal population). Similar results were seen in a second study of 51 patients [
         <a href="#rid47">
          47
         </a>
         ]. Thus, macroprolactinemia appears to be a benign clinical condition [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Although these entities are not of clinical significance directly, they are of clinical significance indirectly because they can be misdiagnosed and treated as prolactin hypersecretion [
         <a href="#rid48">
          48
         </a>
         ]. Misdiagnosis can be avoided by asking the laboratory to pretreat the serum with polyethylene glycol to precipitate the macroprolactin before the immunoassay for prolactin. (See
         <a class="medical medical_review" href="/z/d/html/6638.html" rel="external">
          "Clinical manifestations and evaluation of hyperprolactinemia", section on 'Macroprolactin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H87853623">
         <span class="h3">
          Chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The serum prolactin concentration is high in patients who have chronic kidney disease and returns to normal after kidney transplantation [
         <a href="#rid49">
          49
         </a>
         ]. The major mechanism is a threefold increase in prolactin secretion, and there is a one-third decrease in metabolic clearance rate [
         <a href="#rid50">
          50
         </a>
         ]. Hyperprolactinemia persists, however, during dialysis [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H87853670">
         <span class="h2">
          Chest wall injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest wall injuries, such as severe burns, increase prolactin secretion, presumably due to a neural mechanism similar to that of suckling [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3852282695">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116386.html" rel="external">
          "Society guideline links: Hyperprolactinemia/prolactinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15891.html" rel="external">
          "Patient education: Prolactinoma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2182.html" rel="external">
          "Patient education: High prolactin levels and prolactinomas (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physiologic causes
         </strong>
         – Physiologic causes of hyperprolactinemia include pregnancy, breastfeeding, and stress.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Food has only a small effect on serum prolactin concentrations; therefore, fasting is usually not necessary when having serum prolactin measured. However, if an initial value is mildly elevated (21 to 40 ng/mL), the measurement should be repeated on a fasting specimen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While breastfeeding increases serum prolactin concentrations, nipple stimulation or breast examination does not increase prolactin levels in nonlactating females or males. Therefore, prolactin may be measured after a breast examination. (See
         <a class="local">
          'Physiologic causes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathologic causes
         </strong>
         –
         <strong>
         </strong>
         Pathologic causes of hyperprolactinemia include lactotroph adenomas (prolactinomas), other hypothalamic and pituitary disorders, and medications, most commonly antipsychotics. (See
         <a class="local">
          'Pathologic causes'
         </a>
         above and
         <a class="local">
          'Drug induced'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A germline, loss-of-function mutation in the prolactin receptor gene (
         <em>
          PRLR
         </em>
         ) resulting in prolactin insensitivity has been identified as a cause of familial hyperprolactinemia. (See
         <a class="local">
          'Germline loss-of-function mutation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other causes
         </strong>
         –
         <strong>
         </strong>
         Other causes include idiopathic hyperprolactinemia, hypothyroidism, chest wall injury, chronic kidney disease, and macroprolactinemia due to "big prolactin." (See
         <a class="local">
          'Other causes'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tyson JE, Hwang P, Guyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saraç F, Tütüncüoğlu P, Ozgen AG, et al. Prolactin levels and examination with breast ultrasound or mammography. Adv Ther 2008; 25:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarrell J, Franks S, McInnes R, et al. Breast examination does not elevate serum prolactin. Fertil Steril 1980; 33:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammond KR, Steinkampf MP, Boots LR, Blackwell RE. The effect of routine breast examination on serum prolactin levels. Fertil Steril 1996; 65:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 1977; 296:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander JM, Biller BM, Bikkal H, et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990; 86:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999; 84:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 2007; 28:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corenblum B, Sirek AM, Horvath E, et al. Human mixed somatotrophic and lactotrophic pituitary adenomas. J Clin Endocrinol Metab 1976; 42:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 1994; 41:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delgrange E, Trouillas J, Maiter D, et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 1997; 82:2102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prosser PR, Karam JH, Townsend JJ, Forsham PH. Prolactin-secreting pituitary adenomas in multiple endocrine adenomatosis, type I. Ann Intern Med 1979; 91:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker JD, Grossman A, Anderson JV, et al. Malignant prolactinoma with extracranial metastases: a report of three cases. Clin Endocrinol (Oxf) 1993; 38:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petakov MS, Damjanović SS, Nikolić-Durović MM, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998; 21:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996; 44:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Neurosurgery 1998; 42:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molitch ME. Drugs and prolactin. Pituitary 2008; 11:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 2014; 55:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone-associated hyperprolactinemia. Endocr Pract 2000; 6:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivera JL, Lal S, Ettigi P, et al. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 1976; 5:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bushe C, Yeomans D, Floyd T, Smith SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol 2008; 22:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang YL, Peng M, Zhu G. Topiramate in the treatment of antipsychotic-induced hyperprolactinemia. Med Hypotheses 2020; 138:109607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowen PJ, Sargent PA. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 1997; 11:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meltzer H, Bastani B, Jayathilake K, Maes M. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology 1997; 17:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCallum RW, Sowers JR, Hershman JM, Sturdevant RA. Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab 1976; 42:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sowers JR, Sharp B, McCallum RW. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. J Clin Endocrinol Metab 1982; 54:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steiner J, Cassar J, Mashiter K, et al. Effects of methyldopa on prolactin and growth hormone. Br Med J 1976; 1:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fearrington EL, Rand CH Jr, Rose JD. Hyperprolactinemia-galactorrhea induced by verapamil. Am J Cardiol 1983; 51:1466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veldhuis JD, Borges JL, Drake CR, et al. Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man. J Clin Endocrinol Metab 1985; 60:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romeo JH, Dombrowski R, Kwak YS, et al. Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men. Clin Endocrinol (Oxf) 1996; 45:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newey PJ, Gorvin CM, Cleland SJ, et al. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 2013; 369:2012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin TL, Kim M, Malarkey WB. The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 1985; 60:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sluijmer AV, Lappöhn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 1992; 58:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murdoch FE, Byrne LM, Ariazi EA, et al. Estrogen receptor binding to DNA: affinity for nonpalindromic elements from the rat prolactin gene. Biochemistry 1995; 34:9144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malayer JR, Gorski J. The role of estrogen receptor in modulation of chromatin conformation in the 5' flanking region of the rat prolactin gene. Mol Cell Endocrinol 1995; 113:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frantz AG. Prolactin. N Engl J Med 1978; 298:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med 1978; 64:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snyder PJ, Jacobs LS, Utiger RD, Daughaday WH. Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone. J Clin Invest 1973; 52:2324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groff TR, Shulkin BL, Utiger RD, Talbert LM. Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism. Obstet Gynecol 1984; 63:86S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grubb MR, Chakeres D, Malarkey WB. Patients with primary hypothyroidism presenting as prolactinomas. Am J Med 1987; 83:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanagh-Wright L, Smith TP, Gibney J, McKenna TJ. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol (Oxf) 2009; 70:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie H, Courtney CH, Bell PM, et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001; 86:2743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strachan MW, Teoh WL, Don-Wauchope AC, et al. Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol (Oxf) 2003; 59:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005; 62:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab 1979; 48:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab 1980; 50:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo JC, Beck GJ, Kaysen GA, et al. Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. Hemodial Int 2017; 21:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morley JE, Dawson M, Hodgkinson H, Kalk WJ. Galactorrhea and hyperprolactinemia associated with chest wall injury. J Clin Endocrinol Metab 1977; 45:931.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6626 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5024994" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Studies of prolactin secretion in human pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18224292" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prolactin levels and examination with breast ultrasound or mammography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7351256" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Breast examination does not elevate serum prolactin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8654654" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The effect of routine breast examination on serum prolactin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/840242" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Galactorrhea: a study of 235 cases, including 48 with pituitary tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1973174" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinically nonfunctioning pituitary tumors are monoclonal in origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1977759" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clonal origin of pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10022450" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325339" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pituitary tumor-transforming gene: physiology and implications for tumorigenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/773951" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Human mixed somatotrophic and lactotrophic pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7893282" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Age-related and gender-related occurrence of pituitary adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9215279" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37794" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prolactin-secreting pituitary adenomas in multiple endocrine adenomatosis, type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8319373" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Malignant prolactinoma with extracranial metastases: a report of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9591215" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8729527" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9574657" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18404390" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Drugs and prolactin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24140188" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Psychotropic-induced hyperprolactinemia: a clinical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21296991" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11155212" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Risperidone-associated hyperprolactinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11048906" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/954220" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18477621" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32035285" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Topiramate in the treatment of antipsychotic-induced hyperprolactinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9443523" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9194044" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/777023" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Metoclopramide stimulates prolactin secretion in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7037817" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1268617" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effects of methyldopa on prolactin and growth hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6682619" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hyperprolactinemia-galactorrhea induced by verapamil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3880562" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8977754" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24195502" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mutant prolactin receptor and familial hyperprolactinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2918052" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The natural history of untreated hyperprolactinemia: a prospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3980670" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The natural history of idiopathic hyperprolactinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1624026" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7619813" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Estrogen receptor binding to DNA: affinity for nonpalindromic elements from the rat prolactin gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8674822" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The role of estrogen receptor in modulation of chromatin conformation in the 5' flanking region of the rat prolactin gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/339087" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prolactin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/645742" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Serum prolactin levels in untreated primary hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4199418" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6700889" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3674063" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Patients with primary hypothyroidism presenting as prolactinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18771565" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11397880" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12919157" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical and radiological features of patients with macroprolactinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15943822" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Clinical relevance of macroprolactin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/106066" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7372775" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27774730" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/562902" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Galactorrhea and hyperprolactinemia associated with chest wall injury.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
